Breaking News Instant updates and real-time market news.

AIMT

Aimmune

$21.05

-0.47 (-2.18%)

08:10
08/08/17
08/08
08:10
08/08/17
08:10

Aimmune announces publication of AR101 peanut allergy treatment data

Aimmune Therapeutics announced that its investigational treatment for peanut allergy, AR101, was highlighted in a recent publication by Benaroya Research Institute at Virginia Mason focused on the discovery of an immune cell subset, TH2A cells, that appears to be involved in the pathogenesis of allergies. These allergen-specific T cells are present in people with allergies but nearly entirely absent from people without allergies. The publication, which appeared in the August 2 issue of Science Translational Medicine, also reported that, in a small pilot experiment, AR101 treatment was associated with a significant reduction of TH2A cells in blood samples from a subset of peanut-allergic patients from Aimmune's ARC001 trial. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. Benaroya Research Institute's work with the Aimmune samples potentially represents a new way to measure the allergy process and assess the effectiveness of specific treatments. In addition to the work on peanut allergy, the published article, "A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders," also reported on tests of allergies to grass and tree pollens, cat dander, dust mites, and mold, where TH2A played a pivotal role as well. The researchers found that these TH2A cells associated with stable allergic disease are terminally differentiated CD4+ T cells that exhibit several functional attributes that distinguish them from conventional TH2 cells.

  • 15

    Aug

AIMT Aimmune
$21.05

-0.47 (-2.18%)

03/22/17
PIPR
03/22/17
NO CHANGE
Target $38
PIPR
Overweight
Piper sees Aimmune as having regulatory advantage over DBV
After hosting investor meetings with management, Piper Jaffray analyst Charles Duncan keeps an Overweight rating on Aimmune (AIMT) with a $38 price target. While regulatory visibility will increase in the next 12 months, investors today should focus on response rates for the single highest tolerated dose, or how much peanut can an allergic person tolerate in a single exposure, Duncan tells investors in a research note. The analyst sees Aimmune's AR101 as having generated "uniquely impressive results" on the two key efficacy measures relative to DBV Technologies (DBVT), including both response rates and size of highest tolerated dose. He believes investors may be overlooking catalysts for Aimmune, including up-dosing progress from the PALISADE trial prior to Phase III results around year-end.
02/17/17
PIPR
02/17/17
NO CHANGE
Target $40
PIPR
Overweight
Piper sees Aimmune trial changes as reducing clinical risk
Piper Jaffray analyst Charles Duncan believes the Phase III change announced yesterday by Aimmune Therapeutics (AIMT) reduces clinical risk for the trial read-out, while still addressing a broad group of children and teens more broadly relative to Aimmune's "mindshare competitor" DBV Technologies (DBVT). The PALISADE Phase III primary analysis and initial BLA application will now include ages 4-17, but exclude adult patients, Duncan tells investors in a research note. Following the news, the analyst still believes Aimmune's AR101 will be approved and used in some of adult patients, but points out another trial may be required. He pushed his first AR101 sales estimate in adults back by two years to 2021 in the U.S. market and 2020 to 2022 in the E.U. market. Duncan keeps an Overweight rating on Aimmune with a $40 price target.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
09/26/16
JMPS
09/26/16
INITIATION
Target $30
JMPS
Outperform
Aimmune initiated with an Outperform at JMP Securities
JMP Securities analyst Liisa Bayko initiated Aimmune with an Outperform and a $30 price target. The analyst is confident that AR101 Phase 3 data will show meaningful desensitization to peanuts in allergic children and adults and we will be paying close attention to safety and any discontinuations and projects $1.4B in sales by 2028.

TODAY'S FREE FLY STORIES

PAGS

PagSeguro Digital

$28.75

-3.415 (-10.62%)

14:30
06/19/18
06/19
14:30
06/19/18
14:30
Options
Bullish option plays in PagSegura as shares dive »

Bullish option plays in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

TNXP

Tonix Pharmaceuticals

$4.62

0.04 (0.87%)

14:27
06/19/18
06/19
14:27
06/19/18
14:27
Hot Stocks
Breaking Hot Stocks news story on Tonix Pharmaceuticals »

Regals Capital Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$51.97

0.04 (0.08%)

14:25
06/19/18
06/19
14:25
06/19/18
14:25
Options
Lennar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

FB

Facebook

$196.88

-1.42 (-0.72%)

14:25
06/19/18
06/19
14:25
06/19/18
14:25
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a follow-up hearing »

The Subcommittee on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

ES

Eversource

$55.59

0.505 (0.92%)

, CTWS

Connecticut Water

$66.09

0.34 (0.52%)

14:23
06/19/18
06/19
14:23
06/19/18
14:23
Hot Stocks
Eversource reiterates Connecticut Water proposal, urges holders vote against SJW »

Eversource Energy (ES)…

ES

Eversource

$55.59

0.505 (0.92%)

CTWS

Connecticut Water

$66.09

0.34 (0.52%)

SJW

SJW Corp.

$67.82

1.31 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
06/19/18
06/19
14:17
06/19/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$146.84

-3.69 (-2.45%)

14:16
06/19/18
06/19
14:16
06/19/18
14:16
Hot Stocks
Whirlpool drops further after AHAM data released »

Shares of Whirlpool have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
06/19/18
06/19
14:16
06/19/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYDY

CytoDyn

$0.00

(0.00%)

14:15
06/19/18
06/19
14:15
06/19/18
14:15
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities Association »

Luncheon Meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ZS

Zscaler

$37.56

-2.8 (-6.94%)

14:15
06/19/18
06/19
14:15
06/19/18
14:15
Options
Zscaler Inc put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 11

    Jul

YPF

YPF

$16.57

0.35 (2.16%)

14:05
06/19/18
06/19
14:05
06/19/18
14:05
Options
YPF call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$67.79

-1.96 (-2.81%)

13:55
06/19/18
06/19
13:55
06/19/18
13:55
Options
Xilinx put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$29.19

-0.215 (-0.73%)

13:49
06/19/18
06/19
13:49
06/19/18
13:49
Hot Stocks
Merrill Lynch to pay $42M penalty to settle SEC charges on trade 'masking' »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$195.54

-2.76 (-1.39%)

13:47
06/19/18
06/19
13:47
06/19/18
13:47
Hot Stocks
Facebook takes steps to make video more interactive »

Facebook shares updates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

COTV

Cotiviti Holdings

$44.00

4.105 (10.29%)

13:43
06/19/18
06/19
13:43
06/19/18
13:43
Downgrade
Cotiviti Holdings rating change  »

Cotiviti Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$140.20

34.72 (32.92%)

13:41
06/19/18
06/19
13:41
06/19/18
13:41
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

COTV

Cotiviti Holdings

$44.03

4.14 (10.38%)

13:41
06/19/18
06/19
13:41
06/19/18
13:41
Downgrade
Cotiviti Holdings rating change  »

Cotiviti Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
06/19/18
06/19
13:40
06/19/18
13:40
Options
Alerian MLP attracts a large put buyer »

Alerian MLP attracts a…

FMBH

First Mid-Illinois Bancshares

$41.10

0.25 (0.61%)

13:39
06/19/18
06/19
13:39
06/19/18
13:39
Conference/Events
First Mid-Illinois Bancshares management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 24

    Sep

STE

STERIS

$106.73

-0.82 (-0.76%)

13:37
06/19/18
06/19
13:37
06/19/18
13:37
Conference/Events
STERIS management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

SRPT

Sarepta

$143.85

38.37 (36.38%)

13:35
06/19/18
06/19
13:35
06/19/18
13:35
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

HAIN

Hain Celestial

$29.55

0.69 (2.39%)

13:35
06/19/18
06/19
13:35
06/19/18
13:35
Options
Hain Celestial put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.38

0.175 (0.54%)

, VZ

Verizon

$48.54

1.08 (2.28%)

13:34
06/19/18
06/19
13:34
06/19/18
13:34
Periodicals
AT&T to end sale of user location data to third-party brokers, Verge reports »

AT&T (T) plans to end…

T

AT&T

$32.38

0.175 (0.54%)

VZ

Verizon

$48.54

1.08 (2.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ORCL

Oracle

$46.18

-0.36 (-0.77%)

, MSFT

Microsoft

$100.35

-0.53 (-0.53%)

13:23
06/19/18
06/19
13:23
06/19/18
13:23
Earnings
On The Fly: What to watch for in Oracle's earnings report »

Oracle (ORCL) is…

ORCL

Oracle

$46.18

-0.36 (-0.77%)

MSFT

Microsoft

$100.35

-0.53 (-0.53%)

IBM

IBM

$143.49

-0.96 (-0.66%)

HPE

HP Enterprise

$15.78

-0.14 (-0.88%)

AMZN

Amazon.com

$1,712.48

-11.58 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 10

    Jul

XLU

Utilities SPDR

$49.96

0.27 (0.54%)

13:20
06/19/18
06/19
13:20
06/19/18
13:20
Options
SPDR Repeat put buying in SPDR Utility ETF as the sector sees relative strength »

SPDR Repeat put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.